Ajm. Ferreri et al., Immunoreactivity for p27(kip1) and cyclin E is an independent predictor ofsurvival in primary gastric non-Hodgkin's lymphoma, INT J CANC, 94(4), 2001, pp. 599-604
Our aim was to assess the prognostic implications of the expression of p27(
KIP1) and cyclin E in gastric lymphoma. We investigated the prognostic valu
e of the immunoreactivity of these molecules in 92 cases of primary gastric
lymphoma: 34 LGMLs, 24 DLCLMLs and 34 DLCLs. p27 was positive in 88% of LG
MLs, 71% of DLCLMLs and 32% of DLCLs (p = 0.004); cyclin E was positive in
9%, 33% and 59% of cases, respectively (p < 0.00001). p27/cyclin E immunore
activity significantly correlated with histologic category, stage and LDH s
erum level. p27 immunoreactivity was significantly associated with better s
urvival, whereas cyclin E reactivity was significantly related to worse out
come. Five-year CSS was 94% for patients with P27(+)/cyclin E- phenotype (n
= 42), 79% for p27(+)/cyclin E+ (n = 14) or p27(-)/cyclin E- (n = 16) phen
otype and 60% for p27(-)/cyclin E- phenotype (n = 16) (p = 0.02). The progn
ostic role of p27/cyclin E expression was confirmed when analyzed separatel
y within LGMLs and large-cell lymphomas. Immunoreactivity for p27 and cycli
n E is an independent predictor of survival in PGLs that may be an adjuncti
ve tool in identifying high-risk patients. It correlates with histologic ca
tegory, stage and LDH serum level. p27(-)/cyclin E+ phenotype is associated
with worse survival, probably due to a synergistic effect of both cell-cyc
le defects. The predictive role of these molecules within each histologic g
roup of PGLs deserves to be confirmed in larger series. (C) 2001 Wiley-Liss
, Inc.